Company / Cost of Revenue
Incyte Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$372.1M
FY2025
5-year range
$151.0M / $372.1M
FY2021-FY2025
Trend
+19.2%
vs FY2024
Sector context
#26 of 85
Health Care
What the data says
At $372M, Incyte's cost of revenue ranks #60 of 85 in the Health Care sector. Cost of Revenue has increased for 6 consecutive years, from $79M in FY2019 to $372M in FY2025.
Based on SEC 10-K filings.
$372M in FY2025 with a 5-year CAGR of +31.6%.
Increased from $255M to $372M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +21.6%
- 5-Year CAGR
- +31.6%
- 10-Year CAGR
- -
Sector benchmark
#60 of 85 in Health CareTop 69% of 85This company $372.1M Sector average $2.0B
▼
-81.2% below sector average
Key checks
Key Insights
- Incyte's cost of revenue has grown for 6 consecutive years.
- 5-year CAGR of +31.6%, indicating consistent growth.
- In FY2025, cost of revenue increased 19.2% year-over-year.
- Ranks #26 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.7%
- Strong return on equity: 25.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $372.1M | +19.2% |
| FY2024 | $312.1M | +22.4% |
| FY2023 | $255.0M | +23.2% |
| FY2022 | $207.0M | +37.1% |
| FY2021 | $151.0M | +60.4% |
| FY2020 | $94.1M | +18.4% |
| FY2019 | $79.5M | -15.6% |
| FY2018 | $94.1M | +18.4% |
| FY2017 | $79.5M | +36.6% |
| FY2016 | $58.2M | +115.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026